Lisata Therapeutics
LSTA
43 hedge funds and large institutions have $2.76M invested in Lisata Therapeutics in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 6 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
0.59% less ownership
Funds ownership: 10.89% → 10.31% (-0.59%)
2% less funds holding
Funds holding: 44 → 43 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
76% less capital inflows, than outflows
Capital inflows: $71.4K | Capital outflows: $297K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$27.7K |
| 2 |
Caprock Group
Boise,
Idaho
|
+$12.5K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.5K |
| 4 |
Renaissance Technologies
New York
|
+$7.54K |
| 5 |
Goldman Sachs
New York
|
+$6.71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$114K |
| 2 |
BlackRock Fund Advisors
San Francisco,
California
|
-$59.4K |
| 3 |
Virtu KCG Holdings
New York
|
-$25K |
| 4 |
D.E. Shaw & Co
New York
|
-$22.4K |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
-$16K |
LSTA Hedge Fund Activity: Q2 2016 in Review
43 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q2 2016, worth a combined $2.76M — down 27% from $3.77M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of LSTA and 5 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 9 added.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $27.7K. The largest seller was Great Point Partners, cutting an estimated $114K.
- 43 institutional investors held Lisata Therapeutics (LSTA) as of Q2 2016, down from 44 in Q1 2016.
- Funds reported $2.76M of Lisata Therapeutics stock for Q2 2016, down 27% quarter-over-quarter.
- 5 funds opened new Lisata Therapeutics positions in Q2 2016 and 6 closed out, a net change of -1 holder.
- The largest Lisata Therapeutics buyer in Q2 2016 was Jacobs Levy Equity Management, an estimated $27.7K added.
- The largest Lisata Therapeutics seller in Q2 2016 was Great Point Partners, an estimated $114K sold.
Based on aggregated 13F filings for Q2 2016.